Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis

• Published in: PloS one Vol. 9; no. 7; p. e102484
• Main Authors: Zuo, Pei-Yuan, Chen, Xing-Lin, Liu, Yu-Wei, Xiao, Chang-Liang, Liu, Cheng-Yun
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 15.07.2014; Public Library of Science (PLoS)
• Subjects: Angiogenesis inhibitors; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Bevacizumab; Bias; Brain cancer; Cancer; Cancer patients; Cancer therapies; Care and treatment; Central nervous system; Cerebrovascular system; Chemotherapy; Citation indexes; Clinical trials; Colorectal cancer; Colorectal carcinoma; Complications and side effects; Geriatrics; Health risks; Hemorrhage; Hospitals; Humans; Hypertension; Immunotherapy; Intracranial Hemorrhages - chemically induced; Intracranial Hemorrhages - epidemiology; Ischemia; Laboratories; Lung cancer; Medical research; Medicine and Health Sciences; Meta-analysis; Metastases; Metastasis; Monoclonal antibodies; Neoplasms - drug therapy; Ovarian cancer; Patients; Randomized Controlled Trials as Topic; Risk Factors; Science; Stroke - chemically induced; Stroke - epidemiology; Studies; Systematic review; Targeted cancer therapy; Tumors; Vascular endothelial growth factor; United States > US; China

Arterial ischemia and hemorrhage are associated with bevacizumab, an inhibitor of vascular endothelial growth factor that is widely used to treat many types of cancers. As specific types of arterial ischemia and hemorrhage, cerebrovascular events such as central nervous system (CNS) ischemic events...